Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Yesterday, Sept. 10, 2014, 87 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $485.14 to $187,394,342.10.
Highlighted Stocks Traded by Insiders:
Bristol-Myers Squibb Company (BMY) - FREE Research Report Andreotti Lamberto, who is Chief Executive Officer at Bristol-Myers Squibb Company, sold 50,000 shares at $51.05 on Sept. 10, 2014. Following this transaction, the Chief Executive Officer owned 610,809 shares meaning that the stake was reduced by 7.57% with the 50,000-share transaction.
The shares most recently traded at $50.60, down $0.45, or 0.89% since the insider transaction. Historical insider transactions for Bristol-Myers Squibb Company go as follows:
- 4-Week # shares sold: 20,000
- 12-Week # shares sold: 93,723
- 24-Week # shares sold: 93,723
The average volume for Bristol-Myers Squibb Company has been 6.6 million shares per day over the past 30 days. Bristol-Myers Squibb Company has a market cap of $83.7 billion and is part of the health care sector and drugs industry. Shares are down 3.89% year-to-date as of the close of trading on Wednesday.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The stock currently has a dividend yield of 2.85%. The company has a P/E ratio of 31.4. Currently, there are 9 analysts who rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 8 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on BMY - FREE TheStreet Quant Ratings rates Bristol-Myers Squibb Company as a
buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, notable return on equity, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full
Bristol-Myers Squibb Company Ratings Report from
TheStreet Quant Ratings now.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Ambarella (AMBA) - FREE Research Report LeGall Didier, who is Executive Vice President at Ambarella, sold 15,000 shares at $37.23 on Sept. 10, 2014. Following this transaction, the Executive Vice President owned 56,742 shares meaning that the stake was reduced by 20.91% with the 15,000-share transaction.
Wang Feng-Ming, who is Ceo at Ambarella, sold 15,000 shares at $38.79 on Sept. 10, 2014. Following this transaction, the Ceo owned 326,343 shares meaning that the stake was reduced by 4.39% with the 15,000-share transaction.
The shares most recently traded at $37.40, down $1.39, or 3.71% since the insider transaction. Historical insider transactions for Ambarella go as follows:
- 4-Week # shares sold: 15,000
- 12-Week # shares sold: 30,000
- 24-Week # shares sold: 159,000
The average volume for Ambarella has been 1.2 million shares per day over the past 30 days. Ambarella has a market cap of $1.1 billion and is part of the technology sector and electronics industry. Shares are up 10.45% year-to-date as of the close of trading on Wednesday.
Ambarella, Inc. develops semiconductor processing solutions for video that enable high-definition (HD) video capture, sharing, and display worldwide. The company has a P/E ratio of 40.1. Currently, there are 4 analysts who rate Ambarella a buy, no analysts rate it a sell, and 4 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on AMBA - FREE TheStreet Quant Ratings rates Ambarella as a
hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we also find weaknesses including premium valuation and disappointing return on equity. Get the full
Ambarella Ratings Report from
TheStreet Quant Ratings now.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Mettler-Toledo International (MTD) - FREE Research Report Rauch Waldemar, who is Head of Process Analytics at Mettler-Toledo International, sold 1,000 shares at $270.65 on Sept. 10, 2014. Following this transaction, the Head of Process Analytics owned 10,963 shares meaning that the stake was reduced by 8.36% with the 1,000-share transaction.
The shares most recently traded at $270.20, down $0.45, or 0.17% since the insider transaction. Historical insider transactions for Mettler-Toledo International go as follows:
- 4-Week # shares sold: 2,500
- 12-Week # shares sold: 2,500
- 24-Week # shares sold: 2,500
The average volume for Mettler-Toledo International has been 122,600 shares per day over the past 30 days. Mettler-Toledo International has a market cap of $7.7 billion and is part of the health care sector and health services industry. Shares are up 10.44% year-to-date as of the close of trading on Wednesday.
Mettler-Toledo International Inc. supplies precision instruments and services worldwide. The company operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company has a P/E ratio of 25.7. Currently, there are 2 analysts who rate Mettler-Toledo International a buy, no analysts rate it a sell, and 7 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on MTD - FREE TheStreet Quant Ratings rates Mettler-Toledo International as a
buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, growth in earnings per share, increase in net income, revenue growth and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full
Mettler-Toledo International Ratings Report from
TheStreet Quant Ratings now.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. Data for this article provided by
Zacks Investment Research
